Redeye has revised its estimates for CoinShares in anticipation of its Q1 2025 report, scheduled for...
Ahead of CapMan's Q1 2025 report due on 9 May, we revise our estimates to reflect expected fair valu...
Katalysen Ventures investerar i små onoterade nordeuropeiska bolag genom sitt investeringsramverk Ve...
Q-linea achieved its objective with five ASTar contracts during Q1, supported by a much-improved pip...
Redeye retains its positive view of Carasent following the Q1 report.
Fiskars is highly exposed to the US through Fiskars BA.
Q1'25e organic sales growth of 47% y-o-y Minor estimate changes FVR of SEK 30-45 reiterated What to...
Redeye provides an in-depth review of Episurf Medical’s Q1 report and events during and after the qu...
Redeye comments on OncoZenge’s announcement of an exclusive licensing agreement with Avernus Pharma ...
Slightly softer sales and outlook (-5% vs. ABGSCe in Q4) We cut '25e-'26e sales by 9-8%, EBIT 24-15%...
Redeye offers a preview of Polygien's Q1 results set to be released on April 24.
Redeye updates on Invisio ahead of Q1-results (due 6 May) where we expect continued solid YoY growth...
Redeye provides a brief comment on Smart Eye’s newly proposed long-term incentive program for employ...
Incap had already anticipated a slow start for 2025, and now the entire EMS sector is holding its br...
Redeye expects Smart Eye’s Q1 report, due May 13, to show 12% y/y net sales growth and an EBITDA imp...
Redeye shares its preview of BONESUPPORT’s Q1 2025 results, due April 24.
Redeye returns with an updated take on NextCell following the inconclusive interim analysis, which h...
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for ...
Redeye provides a short comment on the trading update from Cheffelo released earlier this morning.
Redeye sees the acquisition of Welotec as a strategically sound move with relatively low risks.
